Skip to main content
Start of content

HESA Committee Related Document

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.


PRESCRIPTION DRUG STUDY

TERMS OF REFERENCE

That the Standing Committee on Health:

  1. consult, analyse and recommend with respect to the overall system regarding prescription drug research and development, drug approvals, drug licensing, drug marketing (including prices), and drug surveillance;
  2. review the progress of the Common Drug Review process and its capacity for providing access to safe, effective, quality prescription drugs;
  3. consider mechanisms to ensure public input and access to information about the history of any drug’s approval, its safety and efficacy in the marketplace; and its post-market surveillance;
  4. examine relevant international experiences such as the United Kingdom system of patient and public involvement through the National Patient Safety Agency and the Commission for Patient and Public Involvement in Health, the European Medicines Agency efforts at public consultation and the United States Food and Drug Administration’s operation of MedWatch and consumer complaints coordination.